drugset / Trial / NCT04489797

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

NCT04489797

Phase 1 Completed 35 enrolled AstraZeneca Acerta Pharma BV · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is being conducted to support the clinical development of acalabrutinib in participants who need treatment with proton pump inhibitors while taking acalabrutinib.

Timeline

Start
2020-07-20
Primary completion
2020-08-28
Completion
2020-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 100 mg Oral
Subject Rabeprazole Small molecule 20 mg Oral

Indications